Panther is inviting pharmaceutical and biotechnology partners to co-develop higher-efficacy, lower-toxicity, shelf-stable therapies using its MAP platform. We believe rethinking how treatments are ...

Multi-center Phase I clinical study will evaluate the safety and tolerability of a monovalent strain of avian influenza A (H7N9) vaccine delivered intradermally by Vaxxas’ high-density microarray ...

The clinical study aims to evaluate a vaccine for avian influenza A (H7N9) delivered by Vaxxas’ high-density microarray patch (HD-MAP), and is funded by the United States government as a potential ...

Recently published data generated by researchers at The University of Queensland and Vaxxas shows effective delivery of a nucleic acid-based COVID-19 vaccine in a preclinical animal study utilizing ...

Publication in PLoS Medicine reveals groundbreaking clinical research on broad potential of novel high-density microarray patch (HD-MAP) to efficiently deliver vaccines directly to the skin, enhancing ...

Yes, many are attracted to next-generation sequencing, but loyalty to chip-based phenotyping has its rewards, particularly in screens of large sample sets. The microarray, the legacy technology for ...

A single microarray can provide information on the expression of tens of thousands of genes. The amount of information generated by a microarray-based experiment is sufficiently large that no single ...